Sign in Subscribe
3 min read EverHint-Lens

EverHint Lens - Travere Therapeutics, Inc. (TVTX) - Yahoo Top Gainer (+35%) Stock Analysis - April 14, 2026

Travere Therapeutics, Inc. ($TVTX): Healthcare company. trading at $41.55, up 35.3%.
EverHint Lens - Travere Therapeutics, Inc. (TVTX) - Yahoo Top Gainer (+35%) Stock Analysis - April 14, 2026
Travere Therapeutics, Inc

Analysis Date: 2026-04-14
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Travere Therapeutics, Inc. is currently trading at $41.55 (🟢 +35.34% today) with a market capitalization of $3.83B.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.

Price & Valuation

Current Price: $41.55 (at 11:47 AM ET)
Current Volume: 9.5M
Day Range: $39.90 - $42.50
52-Week Range: $13.88 - $42.50
P/E Ratio: -74.64

DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-04-14.

Market Context

Major Indices:

  • S&P 500: $6954.94 (🟢 +1.00%)
  • NASDAQ Composite: $23553.64 (🟢 +1.60%)
  • Dow Jones Industrial Average: $48531.96 (🟢 +0.65%)

Peer Comparison

Peer comparison (11 companies):

  • TVTX - Travere Therapeutics, Inc. ($41.55, +35.3%, $3.83B) ← Current
  • CGON - CG Oncology, Inc. Common stock ($69.97, +3.4%, $5.91B)
  • CNTA - Centessa Pharmaceuticals plc ($39.53, -0.1%, $5.90B)
  • CELC - Celcuity Inc. ($120.68, +0.2%, $5.83B)
  • APGE - Apogee Therapeutics, Inc. ($88.30, +1.8%, $4.94B)
  • XENE - Xenon Pharmaceuticals Inc. ($59.59, +1.7%, $4.70B)
  • LEGN - Legend Biotech Corporation ($18.46, +4.4%, $3.41B)
  • TARS - Tarsus Pharmaceuticals, Inc. ($72.91, +0.4%, $3.10B)
  • IRON - Disc Medicine, Inc. ($70.57, +3.1%, $2.69B)
  • AAPG - Ascentage Pharma Group International ($25.77, +1.3%, $2.40B)
  • RARE - Ultragenyx Pharmaceutical Inc. ($24.51, +3.7%, $2.37B)

Financial Performance

Latest Quarter (2025-12-31):

  • Revenue: $129.69M
  • Net Income: $-21.99M
  • EPS: $-0.24
  • Revenue Growth (QoQ): -21.3%

Stock Split History

TVTX has executed 2 stock split(s) historically

  • 2012-11-02: 1-for-9 split
  • 2009-07-02: 1-for-100 split

Cumulative Split Factor: 0x (1 share in 1987 = 0 shares today)

Most recent split: 1-for-9 on 2012-11-02

Earnings Calendar

Next Earnings Report: 2026-05-07 (After Market Close)

  • EPS Estimate: $-0.23
  • Revenue Estimate: $0.14B

Most Recent Report: 2026-02-19

  • EPS: $0.03 (Est: $0.03) ✗ Miss
  • Revenue: $0.13B

Historical Data: 68 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

  • Target: $54.00 (+30.0% upside)
  • Range: $54.00 - $54.00
  • Median: $54.00

Next Quarter Estimates (2027-12-31):

  • Revenue: $257.61M
  • EPS: $0.41

Analyst Consensus

Overall Rating: Buy

Rating Distribution (159 total ratings):

  • 🟢 Buy/Outperform: 139 (87.4%)
  • ⚪ Hold/Neutral: 17 (10.7%)
  • 🔴 Sell/Underperform: 0 (0.0%)

Recent Analyst Actions:

  • Wedbush (2026-04-14): Maintain Outperform
  • Citigroup (2026-04-14): Maintain Buy
  • Citigroup (2026-03-23): Maintain Buy
  • Piper Sandler (2026-02-06): Maintain Neutral
  • Guggenheim (2026-01-14): Maintain Buy

Consensus based on 159 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 2 trading signal(s) in the last 60 days:

  • 2026-04-02: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $30.44
  • 2026-03-25: Ema10 Price Macd - EMA10_Price_MACD_Buy @ $27.56

Insider Activity

Recent Transactions (Last 10):

  • Buys: 3
  • Sells: 7

Notable Transactions:

  • 2026-04-06: Baynes Roy D. - Buy (Option Exercise, 10,000 shares @ $26.52)
  • 2026-04-06: Baynes Roy D. - Sell (Sale, 10,000 shares @ $33.00)
  • 2026-04-06: Baynes Roy D. - Sell (Option Exercise, 10,000 shares @ $26.52)

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Recent FDA approval of FILSPARI for FSGS has sparked overwhelmingly positive sentiment, with headlines highlighting stock surges, expanded patient reach, and first-in-class status. Strong revenue growth from FILSPARI and positive earnings reports reinforce bullish outlook. Counterpoints like insider selling and securities investigations temper enthusiasm but are overshadowed by approval news.

Key Themes:

  • FDA Approval Success
  • Revenue and Earnings Growth
  • Insider Sales and Investigations

Sentiment: Positive (90% confidence)

Recent News

5 most recent articles covering TVTX:

  • FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients (benzinga.com, 2026-04-14) — Read more
  • Travere Therapeutics Stock Skyrockets On FDA Approval (investors.com, 2026-04-14) — Read more
  • Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript (seekingalpha.com, 2026-04-13) — Read more
  • US FDA expands approval for Travere Therapeutics' drug for rare kidney disease (reuters.com, 2026-04-13) — Read more
  • Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS (businesswire.com, 2026-04-13) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-04-14 08:47:26 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.

Published by:

Vladimir Shamgin

You might also like...

13
Apr

EverHint – Dip & Bounce Mean Reversion for Apr 13, 2026 – 91 Signals – Real Estate Leads (27)

10 signals (from 91 total). Real Estate leads (27). 16 with insider selling. 1 with congressional buying. 1 with congressional selling. price range $6-$935. RSI 52-97. sectors: Real Estate (27), Industrials (18), Financial Services (11). 2 report earnings within 7 days. 31.9% have news.
6 min read
13
Apr

EverHint – EMA10 × EMA30 Crossover – Top 10 Buy and Top 10 Sell Signals for Apr 13, 2026

20 signals (from 90 total). Consumer Cyclical leads (15). 23 with insider selling. 1 with insider buying. 3 with congressional buying. 3 with congressional selling. price range $2-$686. RSI 27-86. sectors: Consumer Cyclical (15), Industrials (14), Financial Services (12).
9 min read
13
Apr

EverHint – EMA10 × Price × MACD – Top 10 Buy Signals for Apr 13, 2026

10 signals (from 24 total). Technology leads (11). 7 with insider selling. 1 with congressional buying. 1 with congressional selling. price range $10-$504. RSI 32-65. sectors: Technology (11), Healthcare (4), Financial Services (3). 1 report earnings within 7 days. 37.5% have news.
8 min read
13
Apr

EverHint – Momentum Swing — Aggressive Momentum for Apr 13, 2026 – 2 Signals – Technology Leads (1)

2 signals. Technology leads (1). 2 with insider selling. price range $63-$128. sectors: Technology (1), Healthcare (1). full analyst coverage, earnings data.
2 min read
13
Apr

EverHint – Momentum Swing — Breakout Standard for Apr 13, 2026 – 9 Signals – Healthcare Leads (4)

9 signals. Healthcare leads (4). 3 with insider selling. price range $10-$257. sectors: Healthcare (4), Technology (2), Basic Materials (2). full analyst coverage, 22.2% have news.
5 min read